MedTrace Logo

Pilot Study of Continuous Glucose Monitoring for Postpartum Glucose Screening

NCT07332416 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1300

Last updated 2026-05-20

No results posted yet for this study

Summary

The oral glucose tolerance test (OGTT) is the standard of care in the postpartum period to screen patients with gestational diabetes mellitus (GDM) for persistent dysglycemia. However, most patients find it burdensome and dread having to do it. Adherence rates are low (18-61%), impeding initiation of follow-up care to improve diabetes-related outcomes in subsequent pregnancies and long-term.

Conditions

  • Gestational Diabetes

Interventions

OTHER

Continuous glucose monitoring for 14 days using the Freestyle LibrePro by Abbott

Postpartum CGM

Sponsors & Collaborators

  • Medstar Health Research Institute

    collaborator OTHER

  • University of North Carolina, Chapel Hill

    collaborator OTHER

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    collaborator NIH

  • Wake Forest University Health Sciences

    lead OTHER

Principal Investigators

  • Katherine A Sauder, MD · Wake Forest University Health Sciences

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2027-01-31
Completion
2027-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07332416 on ClinicalTrials.gov